Thermo Fisher Scientific (TMO) Capital Expenditures (2009 - 2026)

Thermo Fisher Scientific (TMO) has reported Capital Expenditures for 18 consecutive years, with $450.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Capital Expenditures rose 53.06% year-over-year to $450.0 million; the trailing twelve-month figure through Jun 2026 stood at $1.7 billion (up 20.38% YoY), and the FY2025 full-year result was $1.5 billion, up 8.93% from the prior year.
• Capital Expenditures advanced to $450.0 million in Q2 2026 per TMO's latest filing, from $376.0 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $640.0 million in Q2 2022 and bottomed at $272.0 million in Q3 2024.
• Historically, Capital Expenditures has averaged $415.2 million across 5 years, with a median of $404.5 million in 2023.
• The sharpest annual moves came in 2023 and 2026: Capital Expenditures sank 43.87% in 2023, then surged 53.06% in 2026.
• Over 5 years, Capital Expenditures stood at $550.0 million in 2022, then slipped by 26.36% to $405.0 million in 2023, then increased by 18.52% to $480.0 million in 2024, then declined by 3.12% to $465.0 million in 2025, then fell by 3.23% to $450.0 million in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $450.0 million, $376.0 million, and $465.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.